Break it Down: New World Resources fields premium $185M offer to acquire Arizonan copper
Tylah Tully investigates a big $185m premium offer to acquire New World Resources and an emerging Arizonan copper asset.
Stockhead
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News.
Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.
In this episode, host Tylah Tully unpacks the latest from New World Resources (ASX:NWC) and a premium $185 million acquisition offer from London-based Central Asia Metals (LON: CAML) to snap up NWC and its Antler copper project in the Grand Canyon State of Arizona.
New World says it wasn't the only offer on the table, so tune in to hear why the company was unanimous in recommending its acceptance and what's coming next.
While New World Resources is a Stockhead advertiser, it did not sponsor this content.
Originally published as Break it Down: New World Resources fields premium $185M offer to acquire Arizonan copper
ASX dips but Bitcoin hits record on ‘Pizza Day’
ASX stocks wobble, Bitcoin soars and Mayne gets smashed – a messy day so far that has investors reassessing risk and red flags.
AFT Pharmaceutical flags aggressive two-year revenue target
Having posted record revenue of $NZ208 million in the year to March, AFT Pharmaceuticals is confident of hitting its target of 50% growth over the next two years.
ASX slumps 0.6pc as Wall Street retreats
The ASX is on shaky ground this morning, falling 0.6pc in the first hour of trading after Wall Street took its biggest hit since April 2021.
Everything you need to know before the ASX opens.
Good morning! Here’s everything you need to know before the ASX flings open its doors and begins trading today.
ASX biotechs drive paediatric drug advances
ASX biotechs have become well-known for paediatric drug discovery with several life-altering treatments exported to the world.
ASX medtechs eye FDA De Novo, US markets
As Nanosonics scores FDA De Novo win, investors are now watching EMVision’s brain scanner in its US trials with Mayo Clinic